Showing results (91-100 of 105) with videos related to
Sort By:
Pageof 11
NPJ Precision Oncology|February 12, 2024
Genomic and epigenomic basis of breast invasive lobular carcinomas lacking CDH1 genetic alterationsHiginio Dopeso, Andrea M Gazzo, Fatemeh Derakhshan, et al.Nature Communications|March 2, 2025
Multimodal histopathologic models stratify hormone receptor-positive early breast cancerKevin M Boehm, Omar S M El Nahhas, Antonio Marra, et al.Therapeutic Advances in Medical Oncology|December 22, 2023
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitorsEmma Zattarin, Luigi Mariani, Alice Menichetti, et al.JAMA Network Open|February 21, 2025
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast CancerPier Paolo Maria Berton Giachetti, Stefania Morganti, Sara Gandini, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2023
Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell CarcinomaDiana Mandelker, Antonio Marra, Binbin Zheng-Lin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2022
High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial CancerCharles W Ashley, Pier Selenica, Juber Patel, et al.NPJ Breast Cancer|April 17, 2023
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitorsEmma Zattarin, Daniele Presti, Luigi Mariani, et al.Breast (Edinburgh, Scotland)|April 28, 2026
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 studyFrancesca Ligorio, Leonardo Provenzano, Giuseppe Fotia, et al.Breast (Edinburgh, Scotland)|January 31, 2026
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2Giacomo Mazzoli, Leonardo Provenzano, Maria Vittoria Dieci, et al.Cancer Discovery|December 24, 2021
Cancer-Causative Mutations Occurring in Early EmbryogenesisFresia Pareja, Ryan N Ptashkin, David N Brown, et al.Pageof 11